SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

Update Il y a 4 ans
Reference: NCT00335166

Woman and Man

Extract

This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.


Inclusion criteria

  • Early Stage Parkinson Disease


Links